4 results
The primary objective of this study is to evaluate the absolute bioavailability of an oral dose of 10 mg vericiguat (BAY 1021189) given as two 5 mg IR tablets following a high-fat, high calorie meal in comparison to a 14C labeled micro dose of…
Primary Objective•*To evaluate the relative oral bioavailability of SMV, ODV, and AL-335 when administered as different concept fixed-dose combination (FDC) formulations compared to the single agents when administered together, all under fed…
Time to recurrence of sustained VT and/or appropriate ICD therapy; ATP or shock
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…